Table 2.
Basic characteristics of the study group depending on end-point occurrence in the 24-month follow-up.
| All (n = 52) | End point (n = 11; 21.15%) | No end point (n = 41; 78.85%) | p | |
|---|---|---|---|---|
| Age (years)∗ | 51.6 ± 9.1 | 52 ± 9.5 | 51.5 ± 9.2 | 0.87 |
| Men | 90.4% | 100% | 87.8% | 0.57 |
| EF (%)∗ | 28.7 ± 7.5 | 27.9 ± 7.6 | 28.9 ± 7.6 | 0.72 |
| TAPSE (mm)∗ | 20.8 ± 3.9 | 19 ± 3.9 | 21.32 ± 3.8 | 0.08 |
| Ischaemic aetiology | 30.8% | 18.18% | 34.2% | 0.47 |
| BMI (kg/m2)∗ | 28.7 ± 5.0 | 27.4 ± 6.2 | 29.1 ± 4.7 | 0.31 |
| NYHA class III | 25% | 18.18% | 26.8% | 0.71 |
| DMT2 | 28.9% | 36.36% | 26.8% | 0.71 |
| Insulin | 7.7% | 9.1% | 7.3% | 1.00 |
| AHT | 34.6% | 9.1% | 41.5% | 0.07 |
| AF | 38.5% | 36.4% | 68.3% | 0.08 |
| ICD | 51.9% | 63.6% | 48.8% | 0.50 |
| GFR>60 | 84.6% | 81.8% | 85.4% | 1.00 |
| Creatinine (mg/dl)∗∗ | 0.96 (0.85-1.08) | 1.03 (0.96-1.22) | 0.99 (0.81-1.05) | 0.04 |
| Hgb (g/dl)∗∗ | 14.7 (14.05-15.4) | 14.8 (14.1-14.95) | 14.7 (14.1-15.4) | 0.85 |
| HCT (%)∗∗ | 43.55 (41.5-44.7) | 43.5 (42.65-45) | 43.6 (40.3-44.7) | 0.37 |
| PLT (tys./mm3)∗∗ | 205 (165-237.2) | 221 (149.5-268.5) | 201 (172-236) | 0.99 |
| RDW (%)∗∗ | 13.55 (13-14.1) | 13.7 (13.2-14.6) | 13.5 (13-14.1) | 0.50 |
| WBC (tys./mm3)∗∗ | 7.46 (5.95-8.65) | 7.7 (6.11-8.76) | 7.4 (5.68-8.41) | 0.52 |
| Neutrocytes (%)∗∗ | 56.15 (51.4-64.1) | 56.3 (51.9-65.85) | 56 (51.1-62) | 0.82 |
| Hs-CRP (mg/l)∗∗ | 1.10 (0.75-2.46) | 2.16 (0.81-2.27) | 0.96 (0.71-2.72) | 0.90 |
| TnTpre (μg/l)∗∗ | 0.012 (0.008-0.016) | 0.014 (0.01-0.02) | 0.011 (0.008-0.016) | 0.12 |
| TnT post (μg/l)∗∗ | 0.012 (0.009-0.018) | 0.013 (0.01-0.019) | 0.012 (0.008-0.016) | 0.30 |
| TnT δ%∗∗ | 12.3 (4.57-18.35) | 13.5 (7.5-17.65) | 11.1 (3.9-18.2) | 0.51 |
| NT-proBNPpre(pg/ml)∗∗ | 441.5 (181-108) | 758 (472.5-112) | 373 (175-705) | 0.11 |
| NT-proBNPpost (pg/ml)∗∗ | 442 (208-1280) | 955 (512-1380) | 403 (189-876) | 0.10 |
| NT-proBNP δ%∗∗ | 0 (0-8,3) | 0 (-6.25-1.9) | 0 (0-8.3) | 0.28 |
| V02max/VO2peak (l/kg/min)∗ | 18.01 ± 4.96 | 18.22 ± 3.73 | 17.95 ± 5.28 | 0.88 |
| VE/VC02 (%)∗ | 35.40 ± 7.27 | 37.02 ± 6.82 | 34.97 ± 7.40 | 0.41 |
| OUES∗ | 1.90 ± 0.75 | 1.51 ± 0.51 | 2.00 ± 0.78 | 0.05 |
| RER∗ | 1.03 ± 0.18 | 1.05 ± 0.13 | 1.02 ± 0.19 | 0.67 |
| CST pre (ng/ml)∗∗ | 15.95 (13.89-18.8) | 14.23 (11.05-15.82) | 16.86 (14.25-19.46) | 0.03 |
| CST post (ng/ml)∗∗ | 7.04 (4.97-11.08) | 4.81 (2.20-6.25) | 7.82 (5.81-63.48) | 0.002 |
| CST δ%∗∗ | -148 (71-181) | -254 (161-314) | -124 (-71-164) | 0.002 |
| ACEi | 78.9% | 72.7% | 80.5% | 0.68 |
| ARB | 23.1% | 27.3% | 22% | 0.70 |
| Statin | 82.7% | 90.9% | 80.5% | 0.66 |
| Beta-bloker | 100% | 100% | 100% | - |
| ASA | 40.4% | 18.2% | 46.3% | 0.17 |
| Digoxin | 7.7% | 9.1% | 7.3% | 1.00 |
| Spironolakton | 44.2% | 54.6% | 41.5% | 0.51 |
| Eplerenon | 59.6% | 54.6% | 61% | 0.74 |
| Iwabradyna | 11.5% | 27.3% | 7.3% | 0.10 |
| VKA | 34.6% | 72.7% | 24.4% | 0.0048 |
| NonVKA | 5.8% | 0% | 7.3% | 1.00 |
| Amiodaron | 7.7% | 18.2% | 4.9% | 0.19 |
| Furosemid | 25% | 27.3% | 24.4% | 1.00 |
| Torasemid | 36.5% | 54.6% | 31.7% | 0.18 |
| Hydrochlorotiazyd | 15.4% | 0 (0%) | 19.5% | 0.18 |
EF: ejection fraction; TAPSE: tricuspid annular plane systolic excursion; BMI: body mass index; DMT2: diabetes mellitus type 2; AHT: atrial hypertension; AF: atrial fibrillation; ICD: implantable cardioverter-defibrillator; GFR: glomerular filtration rate; Hgb: hemoglobin; HCT: hematocrit; PLT: platelets; RDW: red cell distribution width; WBC: white blood cells; hs-CRP: high-sensitivity C-reactive protein; TnTpre: cardiac troponin T (concentration assessed before physical exertion); TnTpost: concentration assessed immediately after physical exertion; TnT δ%: variability of TnT concentration under the influence of physical effort; NT-proBNP: N-terminal proBNP; VO2max: maximal oxygen consumption; V02peak: peak oxygen uptake; OUES: oxygen uptake efficiency slope; RER: respiratory exchange ratio; CST: catestatin; ACEi: angiotensin-converting-enzyme inhibitors; ARB: angiotensin II receptor blockers; ASA: acetylsalicylic acid; VKA: vitamin K antagonists; nonVKA: nonvitamin K antagonist. Statistically significant results are marked in italics. The results in the tables are presented as follows: ∗means ± standard deviation. ∗∗medians (lower quartile–upper quartile).